ArticleInsights into imaging2026
Performance comparison of gadoxetic and extracellular MRI in diagnosing subcentimeter recurrent HCC after hepatectomy: a modified algorithm.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo compare the performance of gadoxetic acid-enhanced MRI (EOB-MRI) and extracellular contrast agent-enhanced MRI (ECA-MRI) for diagnosing subcentimeter recurrent HCC. MATERIALS AND
methodsBetween January 2017 and December 2023, patients with newly detected suspicious subcentimeter hepatic lesions who underwent both EOB-MRI and ECA-MRI after HCC hepatectomy were retrospectively and consecutively included and divided into training and time-independent test sets. The generalized estimating equation model identified significant MR characteristics in the training set. Diagnostic performances of typical vascular pattern and modified diagnostic algorithms were calculated and compared using the McNemar test in both sets.
resultsA total of 153 patients (mean age, 55.30 ± 11.09; 118 men) with 185 subcentimeter lesions were included. Typical vascular pattern exhibited comparable but unsatisfactory performance across modalities (both sensitivity < 0.50). In the training set, the optimal modified algorithms for EOB-MRI and ECA-MRI combined all identified significant MR characteristics: T2WI mild-to-moderate hyperintensity, nonperipheral washout (on PVP/TP for EOB-MRI; on PVP/DP for ECA-MRI), and restricted diffusion. Both modified algorithms maintained a comparable high specificity compared to the typical vascular pattern. However, the EOB-MRI-based algorithm demonstrated significantly higher sensitivity than the typical vascular pattern (training set, 0.812 vs. 0.400, p < 0.001; time-independent test set, 0.792 vs. 0.375, p = 0.006), an improvement not observed with the ECA-MRI-based algorithm. Furthermore, EOB-MRI-based modified algorithm demonstrated higher sensitivity than its ECA-MRI counterpart (training set, 0.812 vs. 0.425, p < 0.001; time-independent test set, 0.792 vs. 0.417, p = 0.004), with comparable specificity.
conclusionEOB-MRI with a modified algorithm exhibited superior diagnostic performance for subcentimeter recurrent HCC when compared with ECA-MRI. CRITICAL RELEVANCE STATEMENT: This study provides evidence comparing gadoxetic and extracellular MRI in diagnosing subcentimeter recurrent HCC, highlighting the superior diagnostic performance of EOB-MRI-based modified algorithm and its potential to optimize surveillance strategies and clinical decision-making. KEY POINTS: Early detection of subcentimeter recurrent HCC optimizes treatment windows. EOB-MRI-based modified algorithm improves sensitivity while maintaining high specificity. EOB-MRI-based modified algorithm expedites diagnosing subcentimeter recurrences, ultimately facilitating salvage treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.